ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SYH2062

A development code. Also written as “SYH2062 injection”.

Its studies are mostly in Essential Hypertension, led by CSPC Pharmaceutical Group.

Furthest: phase 2, since Jul 30, 20262 company-led studies, 2 open or runningNext primary completion: Jan 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group22 open or runningphase 2since Jul 30, 2026Feb 19, 2025Jan 31, 2027phase 2 · NCT07940075

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 19, 2025First study: phase 1 study in Healthy Chinese VolunteersFirst studyNCT06842537 · 46 planned · China
  2. Jul 30, 2026Phase 2 study in Mild to Moderate Primary HypertensionPhase 2 reachedNCT07940075 · 360 planned · China

Ahead

  1. Jan 31, 2027Primary completion: phase 2 study in Mild to Moderate Primary HypertensionNCT07940075

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07940075Mild to Moderate Primary Hypertension · China2RecruitingJan 31, 2027360
NCT06842537Healthy Chinese Volunteers · China1RecruitingDec 31, 202546

How it is read

Names in the registry

  • “SYH2062”, 1 entry
  • “SYH2062 injection”, 1 entry

Codes read as this program: SYH2062.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.